Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 293 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Simplex Virus Clear all
Completed Phase 3 Interventional Results available

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

NCT01574612
View directory record Official record
Conditions
Herpes Labialis
Interventions
acyclovir/hydrocortisone cream
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Opa-locka, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

NCT03702231
View directory record Official record
Conditions
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Zoster Vaccine Recombinant, Adjuvanted
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational Results available

Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

NCT01878383
View directory record Official record
Conditions
Herpes Simplex Virus
Interventions
Genexpert assay
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
12,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

NCT00306787
View directory record Official record
Conditions
Genital Herpes
Interventions
Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 12, 2026, 8:41 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00636636
View directory record Official record
Conditions
Neuralgia,Postherpetic
Interventions
Gabapentin Extended Release tablets, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational Results available

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Not listed
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents

NCT01262300
View directory record Official record
Conditions
Immunosenescence, Shingles
Interventions
Varicella Zoster Virus Vaccine (Zostavax)
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

NCT00006131
View directory record Official record
Conditions
Herpes Zoster, Immunologic Deficiency Syndromes
Interventions
Valacyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational

Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)

NCT03092505
View directory record Official record
Conditions
Herpes Virus-Related Illnesses
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to Varicella-Zoster Vaccination and Infection

NCT00921999
View directory record Official record
Conditions
Chickenpox, Herpes Zoster
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800
View directory record Official record
Conditions
Herpes Zoster
Interventions
mRNA-1468, Placebo, Shingrix
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
19
States / cities
Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

NCT05371080
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 12, 2026, 8:41 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

NCT06052618
View directory record Official record
Conditions
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

NCT00831103
View directory record Official record
Conditions
Herpes Zoster
Interventions
EPB-348, Valacyclovir
Drug
Lead sponsor
Epiphany Biosciences
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Valacyclovir in Immunocompromised Children

NCT00059592
View directory record Official record
Conditions
Shingles, Bone Marrow Transplantation
Interventions
Valacyclovir
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

NCT02871401
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 12, 2026, 8:41 PM EDT